[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in a virtual investor segment featuring Chief Financial Officer Steve O’Loughlin, who discussed the company’s recently completed oversubscribed...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $22.5M Private Placement Financing

CNS Pharmaceuticals (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement expected to generate approximately $22.5 million in gross proceeds, with participation...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Rami Levin as President and CEO

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under...

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) was featured in a BioMedWire Podcast discussing its sharpened focus on glioblastoma multiforme (“GBM”), one of the deadliest and least treatable forms of cancer....

CNSP : 4.70 (+3.75%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study

CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and...

CNSP : 4.70 (+3.75%)

Barchart Exclusives

What New BlackRock Layoffs Mean for BLK Stock Here
BlackRock is trimming roughly 200 positions even as the asset management giant continues to deliver strong inflows, earnings growth, and expanding margins. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.